Sep 25, 2026Purchase
— · Member of the executive management
Share · 3000.0 shares × 10.3514 CHF · —
COMPANY RESEARCH
Xlife Sciences AG
XLS.SW · Switzerland · Healthcare · Biotechnology
INSIDER SIGNAL
Insider activity score：52.5 / 100
Buyers not named in the filings · 2 purchase line(s) · €67k net purchases
Europe #529 · Switzerland #43
WHY THIS SIGNAL?
Score anatomy
Each bar shows the contribution to the current score; the weights and formula stay unchanged.
Cluster+17.4 / 35
How many distinct insiders bought in the cluster
Purchase size+18.0 / 25
Purchase value relative to company size and liquidity
Role+15.0 / 20
The seniority and relevance of participating insiders
Recency+2.2 / 10
How recently the purchases occurred
Conviction+10.0 / 10
How clearly buying stands out from other activity
What is holding the score back?
- ⚠ Buyer breadth is moderate · fewer than 4 distinct filers
- ⚠ Purchase activity is becoming less recent
- ✓ Strong insider role · c-suite involved
The role contribution uses the inverted role input of the current European model.
Buying concentration
The filings do not name the buyer, so who bought how much cannot be worked out.
This is a ranking under the current European screening rules—not a probability of gain, return forecast, or buy recommendation.
Key purchase quotes (filing currency)
| Filer | Price per unit | Trade date |
|---|---|---|
| — | 10.3514 CHF | Sep 25, 2026 |
| — | 10.35 CHF | Sep 25, 2026 |
Model details
Cluster breakdown (does not change the score)
Not measured: the scoring window holds no purchase filing with both a buyer name and a trade date.
What the filings show
- 🟢 Recent eligible purchase
— · 31k CHF · Price 10.3514 CHF · Sep 25, 2026 - 🟢 PDMR purchase
— · 31k CHF · Price 10.35 CHF · Sep 25, 2026
Insider vs stock price
1 purchase day(s), 2 purchase line(s) in the 180-day window.
Daily close (CHF)Day with an insider purchase
Markers sit on the closing price of the transaction day. They show when insiders traded, not the price they paid or received. "Since" compares that day's close with the last close shown; it is what happened at this company, not a forecast.
If you had followed the purchase
Each row starts on the first close on or after the day a purchase was made public, the earliest a reader could have acted, and ends on the last close shown above.
| Made public | Insiders | In this stock, now | In the median peer stock, now | Difference |
|---|---|---|---|---|
| 2026-09-25 | 1 | 951 −4.9% | 985 −1.5% | −33 −3.3 pts |
0 of 1 disclosure day(s) ended ahead of the median peer stock.
Close to close, before costs, taxes, dividends and currency moves. The peer is the median of the other stocks on the same exchange for which this site holds prices (91 here), not an index. This is what happened, not a forecast: across all purchases on this site the typical gap is close to zero.
Insider timeline
One insider bought, once (25 Sep). The share closed at 10.30 that day and at 9.80 most recently (−4.9%).
Tap an item for what it means.
●A purchase: the bigger the dot, the more was bought
Each dot is one insider's purchases on one day. The dot's area follows the amount: the largest purchase here gets the largest dot. Hold the pointer over a dot to see the date and the amount.
Blue line: this share's price, −50.3% over these six months
The closing price of each day, from 19.71 on 2026-04-21 to 9.80 on 2026-10-07. The line has no scale; read it for high and low: a dot on a low stretch was bought cheaply, a dot on a high stretch was not.
Dashed line: the typical stock on the same exchange, −0.6%
Taken from the 89 other stocks on the same exchange that this site holds prices for. Each is measured from the first day of the window, and every day the middle one is drawn. It starts where the blue line starts, so the gap between the two is the difference: this share −50.3%, the typical one −0.6%, 49.7 points behind. It is not an index and not a comparison within one industry.
▂Grey bars: companies across Europe disclosing purchases each week
A taller bar is a week in which more companies disclosed insider purchases.
Who traded
| Insider | Role | Purchases | Sales | Bought | First purchase | Share price since | Earlier purchases |
|---|---|---|---|---|---|---|---|
| Unknown insider | Associated person | 1 | — | 62.1k CHF | 2026-09-25 | −4.9% | fewer than 5 completed |
Why this score? · Model details
Priority = 100 × Σ(fixed weight × 0–1 rule-based input)
| Factor | Weight | This company input | Point contribution |
|---|---|---|---|
| 15-day buyer breadth (count) | 35% | 0.496; source unavailable, filled with a cohort-neutral value | 17.4 |
| Qualified-buy size | 25% | 0.720 | 18.0 |
| Role informativeness (inverted) | 20% | 0.250 | 5.0 |
| Recency | 10% | 0.218 | 2.2 |
| Buy/sell conviction | 10% | 1.000 | 10.0 |
This is a heuristic ordering under the current rules, not a calibrated return forecast. It explains why candidates rank differently; the public-filing evidence and data limits are shown below.
BULL VS BEAR
Two readings of this buying
The same filings, read two ways. Each line is a fact stored for this company with the number behind it, and appears only when that number crosses a fixed threshold. Neither side is a forecast and no winner is declared.
Since 2026-10-13, neither column has changed. All bull and bear lists, and what followed each line in the past →
Where the evidence comes from
The two kinds of evidence disagree: the purchases themselves carry bull lines (large purchases, senior executive buying), while share price and trading argue against (price down over six months, price trails its sector). No data is held for: short sellers, company actions.
- The insider purchases themselvesBulllarge purchases, senior executive buying2 checked, under the threshold · 3 missing
- Share price and tradingBearprice down over six months, price trails its sector
- Short sellers1 missing
- Company results1 checked, under the threshold · 1 missing
- Company actionsno data held
Bull case · the buying is informative
- Net purchases of €67k equal 0.11% of the company's market value (€60.7M): large for the size of the business.
- The buyers include a senior executive, who sees more of the business than most filers. This site's score gives little or no credit for that: in its backtests purchases by senior executives did no better than other insiders' purchases.Record: after 8,797 earlier disclosures like this, the median 60-session excess return was −3.1%, within 1 percentage point of all comparable disclosures (−3.2%).
Bear case · discount it
- Share price and tradingThe share price is down 50% over six months (three months −46%, one month −25%) and stands 63% below its 52-week high. Insiders have bought into a fall the market has not reversed.Record (nearest stored case: price 20% or more below its prior 52-week high): after 11,077 earlier disclosures like this, the median 60-session excess return was −3.2%, within 1 percentage point of all comparable disclosures (−2.6%).
- Share price and tradingOver three months the share price changed −46% and the median of 271 Healthcare companies changed −6.3%: 39 points behind. The market has marked this company down against its own sector.
Evidence still missing
- This register does not name the filer, so the 2 purchase lines may come from one person or from several. Breadth of buying cannot be judged.
- Only one reading of profitability is held (profit margin <0.01%). Whether earnings and cash flow are rising or falling needs the last two reports side by side.
- This company's market publishes no register of net short positions (it is outside the EU Short Selling Regulation), so whether professional investors are positioned against the buying cannot be read from a public source.
- European notifications have no field saying whether a purchase was pre-arranged; there is no counterpart to the US 10b5-1 box. None of the 2 purchase lines mentions a plan, but a bare “Purchase” does not rule one out.
- The filings give the size of each trade, not what the buyer already held. Whether a purchase added 1% to a personal stake or doubled it is not known.
Checked and under the threshold: 3
- BearNo insider sale is recorded in the same 180 days.
- EitherThe latest purchase is 22 days old. Bull up to 14 days, bear from 90.
- BearProfit margin on the latest captured figures is <0.01%. Counted for the bear side when negative.
Both columns arrange stored facts only. They do not change the insider score or the ranking and are not investment advice.
Signal history
52.5 / 100
Latest recorded score
↓ -8.2 ptssince the first recorded snapshot on 2026-09-25; 23 calendar days observed
- Recorded snapshots
- 19
- First snapshot
- 2026-09-25
There is not yet a 30-calendar-day comparison; earlier scores are not reconstructed. These are raw signal scores saved when each full scoring run completed. They describe changes in research ranking, not price performance or returns.
Why did it change?
Less than 30 days of comparable history is available, so factor movement is not yet decomposed.
Signal score history
Fixed 0–100 scale; dates are spaced by calendar time.
Recent recorded points
- 60.7
- 57.0
- 55.0
- 53.3
- 52.5
View all recorded scores
| Snapshot date | Signal score |
|---|---|
| 2026-09-25 | 60.7 |
| 2026-09-28 | 58.8 |
| 2026-09-29 | 58.0 |
| 2026-09-30 | 57.4 |
| 2026-10-01 | 57.0 |
| 2026-10-02 | 56.6 |
| 2026-10-03 | 56.6 |
| 2026-10-04 | 56.6 |
| 2026-10-05 | 55.4 |
| 2026-10-06 | 55.0 |
| 2026-10-07 | 54.7 |
| 2026-10-08 | 54.5 |
| 2026-10-09 | 54.2 |
| 2026-10-12 | 53.4 |
| 2026-10-13 | 53.3 |
| 2026-10-14 | 53.0 |
| 2026-10-15 | 52.8 |
| 2026-10-16 | 52.7 |
| 2026-10-18 | 52.5 |
Sector context
- Buying breadth
- 6.1% (48 / 792 issuers)
- Sector rank
- #11 / 12
- 7D breadth change
- -0.4 pp · vs 2026-10-12 (6d)
- 30D breadth change
- History building
This is sector-level research context. It does not affect the Insider Signal or ranking.
Insider profile outcomes
The filings for this company do not name the buyer, so past purchases cannot be followed person by person.
Market context
PRICE PERFORMANCE
VOLATILITY & LIQUIDITY
- Volatility
- 58.9%
- Beta
- 0.42
- Avg daily volume
- CHF 39,182.9
VALUATION
- Market cap
- CHF 56.3M
- P/E
- —
FUNDAMENTALS
- Profit margin
- 0.0%
- ROE
- -64.1%
- Industry
- Biotechnology
Prices to 07 Oct 2026: price cache (Eulerpool). From OpenBB/yfinance, captured 29 Sep 2026: Market cap, Profit margin, ROE, Beta, Industry. It does not affect the insider score or rank.
Disclosed net short positions
This country's register of net short positions was not read for this build. That says nothing about whether short positions exist.
Insiders' buying price vs the latest close
The latest close in the price history is more than a week old.
Buying size vs market trading
Market history is too old for this snapshot; ratios are withheld.
Market-data coverage: 249 verified sessions · Latest session: 2026-10-07 · Ratio status: Unavailable
Traded value is estimated as close × shares traded, in major currency units. Includes disclosed qualifying purchases; disclosures may lag. Contractual or planned acquisitions are not necessarily discretionary. Ratios describe relative trading size, not market participation or score contributions.
Latest news
No news has been captured for this company.
Regulatory filings
The filing records held for this company carry no link to the original notice.
Filing evidence
These are underlying national-feed records from the 365-day window ending on the saved ranking snapshot. The score uses only the latest 180 days; older qualifying equity purchases remain visible for audit but do not enter the current score. The original filer, role, transaction classification, instrument, price, volume, value and source fields are retained. The first three rows are shown; remaining records can be unfolded for audit. Other transaction types are retained but excluded from the score.
Excluded transactions & classification
2 qualifying purchase disclosure(s) · 2 transaction line(s)
Sep 25, 2026Purchase
— · Member of the board of directors
Share · 3000.0 shares × 10.35 CHF · —
Showing 2 of 2 matching raw-feed row(s) from the current 365-day research window. Prices and reported values remain in the filing currency and its major unit (for example, UK pence are parsed as GBP). The screen-level € aggregate is separately FX-normalised for research ranking, not a trade-date conversion.
Other disclosed transactions · excluded from score
The underlying filing feed is unavailable in this snapshot; this is not a claim that no filings exist.
Snapshot & identity
- Snapshot date
- 2026-10-18
- Ticker
- XLS.SW
- ISIN
- CH0461929603
- Sector
- Healthcare
- Industry
- Biotechnology
Company logos by Parqet